Anthony Mato, MD, Memorial Sloan Kettering Cancer Center, New York, NY discusses the findings from an examination of the informCLL registry, a prospective observational registry of treated chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) patients with over 1400 patients enrolled. Patient characteristics, biomarker testing, and treatment patterns were analyzed. The registry represents a unique opportunity to assess the impact of these factors in CLL. The analysis was also able to highlight low rates of overall testing, and a knowledge gap in prognostic biomarker testing and treatment choice for high-risk disease. Dr Mato highlights how the registry can answer questions that clinical trials are unable to address and identify areas with a need for change in clinical practice. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.